|Bid||29.26 x 800|
|Ask||70.00 x 800|
|Day's Range||29.35 - 30.11|
|52 Week Range||28.54 - 51.22|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||23.17|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.25|
Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase its innovative commercial and pipeline portfolio at the upcoming American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, March 12-16 in Las Vegas, Nevada. Anika will be exhibiting its injectable, HA-based, surgical bone repair therapy in addition to its viscosupplement (CINGAL) and cartilage repair (HYALOFAST) solutions. “We’re excited to preview our bone repair therapy at the 2019 AAOS Annual Meeting, the largest gathering of orthopedic surgery professionals from around the world,” said Joseph Darling, President and CEO, Anika Therapeutics.
Anika (ANIK) delivered earnings and revenue surprises of 50.00% and 2.81%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Bedford, Massachusetts-based company said it had net income of 54 cents. The medical technology company posted revenue of $27 million in the period. For the year, the company ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Anika Therapeutics, Inc. (NASDAQ:ANIK), which has zero-debt on its balanceRead More...
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anika Therapeutics, Inc. today announced that the Company plans to issue its fourth-quarter and full-year 2018 financial results after the close of the market on Thursday, February 21, 2019 and hold its investor conference call on the same day, Thursday, February 21, 2019, at 5:00 p.m.
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Anika Therapeutics, Inc. (NASDAQ:ANIK), which is in the medical equipment business, and is based in United States, saw a double-digit share price rise of over 10% in the past couple Read More...
Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced plans to showcase HYALOFAST, a biodegradable, HA-based cartilage repair scaffold, at the 2019 International Cartilage Repair Society Summit.
According to the GuruFocus All-in-One Screener, the following stocks are trading at a discount and have positive three- to five-year future earnings estimates. Warning! GuruFocus has detected 3 Warning Signs with VIA. The discounted cash flow calculator gives the stock a fair value of $52.04 per share, suggesting it has a 44% margin of safety.
Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Anika Therapeutics, Inc. (NASDAQ:ANIK). Is Anika Therapeutics, Inc. (NASDAQ:ANIK) worth […]
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Read More...
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
Anika Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced plans to showcase its entire Orthobiologics franchise, including HYALOFAST, at the upcoming ICRS Focus Meeting in Milan, Italy at the Humanitas Research University.
Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that it has resumed global distribution of its solid HA-based treatments, including HYALOFAST, a biodegradable, HA-based cartilage repair scaffold, after a voluntary, non-safety related recall in the second quarter of 2018. Following recent regulatory approvals in Thailand, the United Arab Emirates and Colombia, HYALOFAST has a commercial footprint in approximately 15 countries. “Since May, our quality and operations teams have worked tirelessly to get us back on line to resume shipments before the end of this year, and we’ve delivered on that promise,” said Joseph Darling, President and CEO, Anika Therapeutics.